Protect Muscle While Losing Weight on GLP-1 Therapy
For patients using GLP-1 and incretin-based weight-loss therapy.
Weight loss should not come at the expense of lean tissue. MyoGuard provides physician-guided muscle preservation support through the Sarcopenia Risk Index (SRI).
No account required • Takes about 60 seconds
Built on: STEP Trials • EWGSOP2 • PROT-AGE • Peer-Reviewed Evidence
Muscle Protection Assessment
Powered by the Sarcopenia Risk Index (SRI)
Body metrics
GLP-1 therapy
Symptoms & lifestyle
Recovery environment
Typical adult range: 5–9 hours
Sleep duration is displayed as a recovery context indicator. Nocturnal GH and IGF-1 secretion support muscle protein synthesis — adequate sleep optimises your protocol outcomes. This parameter is not incorporated into the sarcopenia risk score.
MyoGuard Clinical Oversight · For educational use only · Not a substitute for clinical consultation
How MyoGuard Helps
Real-time sarcopenia risk
SRI generated against your GLP-1 dose stage and clinical protein floor
Personalised protein targets
Protein and fibre guidance calibrated to your weight, dose, and GI burden
Evidence-based supplement guidance
Protocol stack grounded in peer-reviewed nutrition science
Continuous adherence monitoring
Weekly check-ins with longitudinal tracking of your muscle preservation indicators